Product Name: Entacapone
Synonyms: (E)-2-Cyano-3-(3，4-dihydroxy-5-nitrophenyl)-N，N-diethyl-2-pmpenamide;Entacapone (150 mg);(2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enaMide;2-PropenaMide,2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-, (2E)-;(E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylacrylamide;Entacapone (isomer E);(E)-2-cyano-3-(5-(dihydroxyamino)-3,4-dioxocyclohexa-1,5-dienyl)-N,N-diethylacrylamide;ENTACAPONE
CAS: 130929-57-6
MF: C14H15N3O5
MW: 305.29
EINECS: 212-686-0
Product Categories: Histone Methyltransf;Intermediates & Fine Chemicals;Pharmaceuticals
Entacapone was introduced in Finland, Germany and Sweden as an adjunctive treatment with L-dopa in Parkinson’s disease. Entacapone is the second drug in its class to reach the market; it can be obtained by basecatalyzed condensation of the corresponding benzaldehyde with a cyanoacetamide. Entacapone is a highly selective and orally-active catechol-0- methyltransferase (COMT) inhibitor ; by inhibiting metabolism of L-dopa when given as an adjuvant in patients with Parkinson’s disease, Entacapone markedly prolongs the effects of L-dopa and improves its bioavailability. Results from clinical studies showed that 200mglday Entacapone coadministered with L-dopa lowered the dose of the latter required to reduce fluctuations in motor performance.
China
